Directorio

We are doing this study to compare the early treatment (before you have cancer symptoms) of Venetoclax and Obitnutuzumab (V-O) to the usual treatment of V-O after you have cancer symptoms. This study will help doctors figure out if early treatment is better, the same, or worse than the usual approach of waiting until the patient has cancer symptoms before starting treatment.

We are doing this study to compare the usual treatment for neuroendocrine carcinomas to using atezolizumab plus the usual treatment. Another purpose is to compare using atezolizumab just at the beginning of treatment to continuing it beyond the initial treatment.

We are doing this study to collect data and samples to store them for future research. We hope the data and samples will lead to improved treatment of patients who are seriously ill or have been injured.

This is a biosample collection study for people in the Surgical Critical Initiative Tissue and Data Acquisition Study If you join this study, you will: - Have blood drawn (an extra 2 teaspoons) at time of your injury or surgery, on Days 1, 3 and 7 after your injury or surgery, and weekly while you are in the hospital. We may also collect fluid or tissue from your wound and pictures of it We will also collect blood near time of surgery or if you get worse. We will also ask to use data collected under TDAP for analyses.

We are doing this to see the effects of giving long-term red blood cell exchange transfusion to patients with sickle cell disease (SCD). We want to know if exchange blood transfusion may help with serious complications of SCD or reduce the chances of a new, serious problem happening.

We are doing this study to find the most effective, safe dose of an experimental drug called SGR-1505 (the study drug). We want to know how well this study drug specifically targets a protein related to your B-cell cancer.

We are doing this study to determine whether specialty palliative care or primary palliative care is the best way to improve the quality of life and experience of patients and their caregivers.

We are doing this study to find out if an investigational drug called RGN-259 Thymosin Beta 4 eye drops solution (the study drug) is a safe and effective option for the treatment of neurotrophic keratopathy.